SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate its massive cash pile and underperformance relative to the broader market, with many pinning their hopes on the upcoming annual meeting for clarity on CEO Greg Abels leadership strategy. Community sentiment is deeply divided between long-term supporters viewing the stock as a defensive value anchor and frustrated traders rotating into higher-growth AI and tech sectors.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding Jupiter's $UPDOG token is highlighting its long-term presence on the Solana network and its placement on the Jupiter Strict List. Active discussions are centered on persistent meme-based engagement, community building, and efforts to drive visibility through ongoing social outreach.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a stake in the company ahead of a potential acquisition offer, sparking widespread community debate over the feasibility of such a deal given the massive disparity in their market capitalizations. Investors are actively discussing the potential strategic fit for a retail-tech pivot versus concerns that the news is an elaborate market-driven distraction.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

$SPERMWHALE is trending as investors actively discuss its potential for rapid price surges, utility features like buybacks, and its status within the volatile meme coin community. The conversation is driven by a mix of speculative enthusiasm for breaking new all-time highs and persistent debate regarding the project's sustainability compared to other emerging tokens.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after reports surfaced that the company is preparing an offer to acquire eBay, fueling aggressive retail speculation about a potential strategic pivot into e-commerce. While the community is actively debating the feasibility of the merger given the valuation gap, the news has ignited significant options activity and excitement over a potential short squeeze.

Liquid Mercury is a technology company that provides institutional-grade trading infrastructure, workflow automation, and Real World Asset (RWA) marketplaces. Its platform is designed to meet the performance, security, and reporting standards expected by the most demanding traditional finance institutions.  At the core of the ecosystem is MERC, an ERC-20 utility token that delivers value to users in three primary ways:  1. Discount Farming via Staking  MERC holders can participate in a “Discount Farming Staking Program,” which enables users to earn monthly Element Tokens (ETs) by staking their MERC tokens. These ETs can be:  - Applied toward Liquid Mercury invoices for service discounts, if you're a customer. - Traded for cash equivalents on a private secondary marketplace where ET holders and Liquid Mercury customers can buy and sell ETs.  2. Access to Premium Features and Staking Rewards  Staking MERC also unlocks:  - Access to exclusive research, curated trading tools, and trading rebates. - Annual staking rewards paid in MERC, currently set at 10% per year.  3. Utility in the Expansion of Real World Asset (RWA) Markets  As Liquid Mercury grows its footprint in the RWA sector, the role of the MERC token will expand accordingly, powering participation and utility within tokenized asset marketplaces.

Liquid Mercury

Liquid Mercury is gaining traction as community members highlight continuous development updates, including new website features and the TokenBloq integration. Investors are actively tracking the project's institutional-grade infrastructure and its high-profile backing as part of broader ecosystem partnerships.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to surging M&A speculation, with renewed reports from French media identifying Eli Lilly and AstraZeneca as potential suitors. The community is focused on the stock's M&A premium and recent positive data readouts, fueling intense interest in a possible high-value acquisition of the company's inflammatory disease platform.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is currently trending as holders aggressively buy the dip, fueled by speculation that potential upcoming listings on major US exchanges could trigger a significant breakout. Community sentiment remains intensely bullish, with many investors actively accumulating and pushing for organic growth while dismissing bearish pullbacks as opportunities to lower their entry points.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending as investors react to a significant strategic oncology collaboration with Astellas Pharma and strong clinical trial results for its prostate cancer drug, VIR-5500. While the community is actively debating the impact of a recent public stock offering and the potential for a short squeeze, many are focused on the long-term value of the company's strengthened cash position and its dual franchises.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to positive clinical data for its lead oral drug, Soquelitinib, which has fueled speculation regarding potential M&A activity and institutional accumulation. While the community is debating whether the stock is undergoing a healthy consolidation or a speculative pump, discussion remains heavily focused on upcoming clinical milestones and the potential for a major pharmaceutical acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army...

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?

BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.

New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study...

bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath Lung test will be featured at...

<ul class="summary-bullets"><li>CyPath uses flow cytometry and AI to provide “likely” or “unlikely” malignancy results.</li><li>Rising pulmonary nodules and lung cancer survivors could drive market revenue to over $560 million.</li><li>bioAffinity’s commercial initiatives include expanding physician sites, peer education, and integration into clinical workflows.</li></ul>bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.CyPath Lung combines flow cytometry with AI to deliver clear “likely” or “unlikely” malignancy results to physicians. Real-world applications suggest the test can detect lung cancer at Stage 1A, improving treatment outcomes, and reduce unnecessary invasive procedures when malignancy risk is low.<h2 class="st-heading-2">Strong Market Demand</h2>Estimates from the U.S. Preventive Services Task Force suggest that indeterminate pulmonary nodules detected in the U.S. will increase 62%, from 2.9 million in 2025 to 4.7 million by 2030. The number of lung cancer survivors is also expected to rise from 680,000 to more than 871,000 over the same period.&nbsp;Capturing just 10% of these markets could generate $358 million in revenue for CyPath Lung, growing to over $560 million in five years, driven by a 10% compound annual growth rate fueled by broader screening adoption and AI-enhanced imaging technologies.<blockquote>“CyPath Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.”-Maria Zannes, President and CEO of bioAffinity Technologies</blockquote>Following the update, bioAffinity stock traded over 8% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘low’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Commercial Strategy Boosts Adoption</h2>bioAffinity has focused on CyPath Lung as its flagship product, expanding ordering sites, promoting peer-to-peer education among pulmonologists, and integrating the test into routine lung cancer risk assessment workflows.&nbsp;Revenue for CyPath Lung rose 87% year-over-year in 2025, while test units sold grew 99% compared to 2024.BIAF stock has gained over 260% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-struggles-weakest-magnificent-seven-in-q1-and-now-it-is-spending-5-5-b-more-on-ai/cZ7HZG9RInw">MSFT Stock Struggles As Weakest Of Magnificent Seven In Q1 – And Now It Is Spending $5.5B More On AI</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAffinity Technologies logo is displayed on the screen of a tablet.

BIAF Stock Gains As CyPath Sales Surge 146% In Q1

bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.

Equity

The test is capable of identifying lung cancer at Stage 1A, enhancing chances for effective treatment.


bioAffinity Technologies CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...

<ul class="summary-bullets"><li>Urban-Gro’s merger with Flash Sports and Media marked a notable transition beyond indoor agriculture into sports-focused media.</li><li>Turbo Energy benefited from escalating tensions in the Middle East that sent energy prices higher.</li><li>bioAffinity reported strong sales growth for its lung diagnostic product, CyPath, and ambitious 100% growth guidance in 2026.</li></ul>A handful of lesser-known companies stole the spotlight in March, surging ahead of the broader market amid decisive operational shifts and real-world execution.Urban-gro, Inc. (UGRO), Turbo Energy S.A. (TURB), AleAnna, Inc. (ANNA), EpicQuest Education Group International (EEIQ), and bioAffinity Technologies, Inc. (BIAF) posted triple-digit percent gains during the month.<h2 class="st-heading-2">Shift Toward Execution Over Hype</h2>While large-cap technology names struggled amid sector rotation, these smaller firms capitalized on geopolitical disruptions, internal restructuring, and performance milestones to deliver outsized gains.Urban-Gro staged a sharp recovery after regaining compliance with Nasdaq listing standards in early March. The removal of delisting concerns lifted investor confidence. At the same time, its merger with Flash Sports and Media marked a notable transition beyond indoor agriculture into sports-focused media and marketing, reshaping its growth narrative.<a href="https://stocktwits.com/symbol/UGRO">Urban-Gro stock</a> traded over 4% higher in Tuesday’s premarket and has surged over 731% in March.&nbsp;<h2 class="st-heading-2">Shielding From Energy Shocks And The European LNG Supply Crisis</h2>Turbo Energy benefited from escalating tensions in the Middle East that sent energy prices higher. Its AI-powered energy storage systems gained traction among European industrial clients seeking to stabilize operating costs. On March 6, the company disclosed a $53 million backlog in industrial orders, further reinforcing optimism around its standing in the energy security space.&nbsp;<a href="https://stocktwits.com/symbol/TURB">Turbo Energy stock</a> traded over 6% lower in Tuesday’s premarket and has posted a gain of over 314% in March.&nbsp;&nbsp;AleAnna surged as supply shocks rattled global liquefied natural gas markets. Disruptions tied to the Middle East conflict tightened availability, elevating the strategic importance of the company’s Italian gas assets.&nbsp;On March 12, the company announced significant increases to its proved reserves across key Po Valley fields, following the completion of its final 2025 reserves report.&nbsp;<a href="https://stocktwits.com/symbol/ANNA">AleAnna stock</a> traded over 2% higher in Tuesday’s premarket, with over 25% gains in March.&nbsp;<h2 class="st-heading-2">Low Float And Growth Milestones&nbsp;</h2>After completing a 1-for-16 reverse stock split in late February, EpicQuest Education Group began March with a reduced float of about 1.48 million shares, allowing for extreme price velocity on relatively low buying volume.<a href="https://stocktwits.com/symbol/EEIQ">EpicQuest stock</a> has surged by over 242% in March.&nbsp;Meanwhile bioAffinity Technologies delivered one of the most dramatic moves, nearly doubling in a single trading session on March 13. Strong sales growth for its lung diagnostic product, CyPath, and ambitious 100% growth guidance in 2026, suggested the company had successfully transitioned from the development stage to revenue-generating operations.<a href="https://stocktwits.com/symbol/BIAF">BIAF stock</a> has increased by over 233% in March.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-red-cat-holding-stock-up-premarket/cZEPrK6RIVP">Why Is RCAT Stock Rising Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

UGRO, TURB, ANNA, EEIQ, BIAF: These Five Stocks Outpaced Big Tech With Massive March Returns

As big tech faltered during sector shifts, share prices of some of the smaller companies surged amid restructuring efforts and key business achievements.

What's Going On With bioAffinity Technologies Stock Wednesday?

bioAffinity Technologies Inc (NASDAQ: BIAF) shares trade higher in Wednesday's premarket after announcing a live virtual roundtable for its CyPath Lung test.read more...

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath Lung into Pulmonary Practice

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced it will host the first of a series of live...

BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally

The stock has been on a sharp uptrend, gaining more than 160% over the past week on the back of bullish CyPath Lung estimates.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Current Price	$2.19
Prev Close	$2.49
Open	$2.41
Dividend Yield	0.00%
50-Day Moving Average	$2.50
Beta	1.60
Avg. Volume	1.09M
PE Ratio	-0.14

52-Week High	$15.00
52-Week Low	$0.693
Market Capitalization	$9.85M
EPS (Annual)	-$8.66
Price to Book	1.35
Revenue Per Employee	$108,104.54

BIAF
BioAffinity Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIAF News

BIAFBioAffinity Technologies Inc